To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at For Technical questions please contact Thank you.

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >

Gastrointestinal Cancer

Gastric and intestinal cancers interfere with the body’s ability to digest and absorb nutrients. Gastric, or stomach, cancers are frequently associated with Helicobacter pylori infections and smoking. The chronic inflammation caused by these mediators may contribute significantly to the pathogenesis of gastric cancer. In colon cancer, polyps (benign aggregates of cells) protrude into the lumen of the colon. These polyps may eventually become cancerous and spread throughout the body. ATCC’s collection of cells has been used in the development of a number of biomarker and personalized assays.

Stomach Cancer Cell Panel

The ATCC Stomach Cancer Cell Line Panel comprises six cell lines that may be used to enhance your biological understanding of top genetic alterations across tumor types and support chemotherapeutic assay development.

Stomach Cancer Cell Panel

Cells of the Digestive System

ATCC's vast collection of stomach, esophagus, small intestine, and colon cells includes cell lines derived from normal and diseased tissues of multiple species. ATCC also carries cells derived from the accessory organs of the digestive system, such as the liver and the pancreas.

Esophageal Cell Lines
Small Intestine Cell Lines
Colon Cell Lines
Hepatic Cell Lines
Pancreatic Cell Lines

Colon Cancer Tumor Cell Panels

Mutations in BRAF and KRAS are important predictors of patient response to chemotherapy. ATCC has developed two colon cancer panels with varying degrees of genetic complexity that are organized by BRAF or KRAS mutations. 

Colon Cancer Cell Panels